Angion and Vifor Pharma Report Completion of Patient Enrollment in P-II AKI-002-15 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

 Angion and Vifor Pharma Report Completion of Patient Enrollment in P-II AKI-002-15 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Angion and Vifor Pharma Report Completion of Patient Enrollment in P-II AKI-002-15 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Shots:

  • The companies have completed the enrolment in P-II AKI-002-15 study evaluating the safety and efficacy of ANG-3777 (2.0 mg/kg, IV) vs PBO over 4 days in patients with CSA-AKI across the US, Canada, Brazil, and Georgia
  • The first dose was given within 4hrs. of the completion of surgery with subsequent doses @24hrs. interval. The 1EP is an increased percentage of serum creatinine above baseline, starting from 24hrs. after the end of cardiopulmonary bypass surgery through day 6.
  • The companies plan to initiate confirmatory trial early in 2022, following the results of P-II study as well as discussions with the FDA and other relevant health authorities. The topline data is expected in H2’21

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Linkedin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post